Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioGend Therapeutics Co's EBIT per Share for the
three
months ended in Dec. 2025 was NT$-0.21.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-0.83.
During the past 3 years, the average EBIT per Share Growth Rate was 25.20% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 12.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for BioGend Therapeutics Co's EBIT per Share or its related term are showing as below:
ROCO:6733'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -1.6 Med: 15.4 Max: 25.2
Current: 25.2
During the past 10 years, the highest 3-Year average EBIT per Share Growth Rate of BioGend Therapeutics Co was 25.20% per year. The lowest was -1.60% per year. And the median was 15.40% per year.
ROCO:6733's 3-Year EBIT Growth Rate is ranked better than 62.23% of 1173
companies
in the Biotechnology industry
Industry Median: 15.5
vs ROCO:6733: 25.20
BioGend Therapeutics Co (ROCO:6733) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
BioGend Therapeutics Co EBIT per Share Related Terms
BioGend Therapeutics Co EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-0.83
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioGend Therapeutics Co (ROCO:6733) has a EBIT per Share of NT$-0.83 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on BioGend Therapeutics Co and its competitors. According to the industry distribution chart, BioGend Therapeutics Co ranks #443 out of 1173 companies in the Biotechnology industry, placing it in the top 37.8%.
Is BioGend Therapeutics Co's EBIT per Share too high?
BioGend Therapeutics Co's current EBIT per Share is NT$-0.83. Based on the distribution chart, BioGend Therapeutics Co ranks #443 out of 1173 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BioGend Therapeutics Co has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioGend Therapeutics Co's EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioGend Therapeutics Co ranks #443 out of 1173 companies for EBIT per Share. This puts BioGend Therapeutics Co in the upper half of its industry. The industry median EBIT per Share is 15.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.50, based on 1,173 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on BioGend Therapeutics Co and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioGend Therapeutics Co's current EBIT per Share is NT$-0.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGend Therapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, BioGend Therapeutics Co (ROCO:6733) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$70.53, compared to a current price of NT$24.10 — trading 65.8% below its estimated fair value. The current EBIT per Share is NT$-0.83. BioGend Therapeutics Co's overall GF Score™ is 74/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For BioGend Therapeutics Co (ROCO:6733), the current EBIT per Share is NT$-0.83 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioGend Therapeutics Co (ROCO:6733) Overvalued in 2026?
Based on GuruFocus' analysis, BioGend Therapeutics Co stock appears to be undervalued.
The current stock price of NT$24.10 is trading 65.8% below its estimated GF Value™ of NT$70.53.
GuruFocus considers BioGend Therapeutics Co to be Significantly Undervalued.
Key valuation signals for ROCO:6733:
EBIT per Share: NT$-0.83
GF Value™: NT$70.53 vs. price of NT$24.10 (65.8% below fair value)
No single metric tells the full story. See the ROCO:6733 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioGend Therapeutics Co Ltd is a Taiwan-based company involved in the research and development of orthopedic medical equipment and related products, and the sale of related products. It is involved in the research and development of inventive cartilage repair technology and products, adipose stem cell extraction technology, and others. Geographically, the company generates a majority of its revenue from Taiwan, followed by China, Malaysia, and other regions.
74GF Score
Get the complete analysis for ROCO:6733
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6733 has been successfully added to your 
